UB Paderborn / Katalog / Suche / in CDI

Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial

The Lancet (British edition), 2021-05, Vol.397 (10286), p.1736-1748

2021

Link zum Volltext

Verfügbarkeit prüfen

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2021-04, Vol.325 (14), p.1403

2021

Link zum Volltext

Verfügbarkeit prüfen

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2022-01, Vol.327 (2), p.138

2022

Link zum Volltext

Verfügbarkeit prüfen

A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity‐related risk factors (COR‐II)

Obesity (Silver Spring, Md.), 2013-05, Vol.21 (5), p.935-943

2013

Link zum Volltext

Verfügbarkeit prüfen

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2021-04, Vol.325 (14), p.1414

2021

Link zum Volltext

Verfügbarkeit prüfen

Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2023-08, Vol.402 (10403), p.705-719

2023

Link zum Volltext

Verfügbarkeit prüfen

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5

Obesity (Silver Spring, Md.), 2020-06, Vol.28 (6), p.1050-1061

2020

Link zum Volltext

Verfügbarkeit prüfen

Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses

Diabetes, obesity & metabolism, 2023-02, Vol.25 (2), p.468-478

2023

Link zum Volltext

Verfügbarkeit prüfen

Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice

Postgraduate medicine, 2022, Vol.134 (1), p.14-19

2022

Link zum Volltext

Verfügbarkeit prüfen

Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss

Diabetes, obesity & metabolism, 2022-01, Vol.24 (1), p.94-105

2022

Link zum Volltext

Verfügbarkeit prüfen

Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program

Postgraduate medicine, 2022-04, Vol.134 (sup1), p.28-36

2022

Link zum Volltext

Verfügbarkeit prüfen

A Systematic Review of Dietary Supplements and Alternative Therapies for Weight Loss

Obesity (Silver Spring, Md.), 2021-07, Vol.29 (7), p.1102-1113

2021

Link zum Volltext

Verfügbarkeit prüfen

Weight History in Clinical Practice: The State of the Science and Future Directions

Obesity (Silver Spring, Md.), 2020-01, Vol.28 (1), p.9-17

2020

Link zum Volltext

Verfügbarkeit prüfen

Randomized controlled trial of a nationally available weight control program tailored for adults with type 2 diabetes

Obesity (Silver Spring, Md.), 2016-11, Vol.24 (11), p.2269-2277

2016

Link zum Volltext

Verfügbarkeit prüfen

Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials

EClinicalMedicine, 2023-01, Vol.55, p.101737-101737, Article 101737

2023

Link zum Volltext

Verfügbarkeit prüfen

Changes in weight control behaviors and hedonic hunger in a commercial weight management program adapted for individuals with type 2 diabetes

International Journal of Obesity, 2020-05, Vol.44 (5), p.990-998

2020

Link zum Volltext

Verfügbarkeit prüfen

Radioimmunoassay and Tandem Mass Spectrometry Measurement of Bedtime Salivary Cortisol Levels: A Comparison of Assays to Establish Hypercortisolism

The journal of clinical endocrinology and metabolism, 2007-08, Vol.92 (8), p.3102-3107

2007

Link zum Volltext

Verfügbarkeit prüfen

Effects of Dietary Self-Monitoring, Physical Activity, Liraglutide 3.0 mg, and Placebo on Weight Loss in the SCALE IBT Trial

Obesity facts, 2020-12, Vol.13 (6), p.572-583

2020

Link zum Volltext

Verfügbarkeit prüfen

Impact on psychosocial outcomes of a nationally available weight management program tailored for individuals with type 2 diabetes: Results of a randomized controlled trial

Journal of diabetes and its complications, 2017-05, Vol.31 (5), p.891-897

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of semaglutide 2.4 mg by race and ethnicity: A post hoc analysis of three randomized controlled trials

Obesity (Silver Spring, Md.), 2024-07, Vol.32 (7), p.1268-1280

2024

Link zum Volltext

Verfügbarkeit prüfen

Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial

Obesity (Silver Spring, Md.), 2020-03, Vol.28 (3), p.529-536

2020

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Semaglutide 2.4 mg by Race and Ethnicity

Obesity (Silver Spring, Md.), 2022-11, Vol.30, p.192-192

2022

Link zum Volltext

Verfügbarkeit prüfen

A review of topiramate and phentermine: a combined therapeutic approach for obesity

Clinical lipidology, 2012-02, Vol.7 (1), p.13-25

2012

Link zum Volltext

Verfügbarkeit prüfen

Once Daily Oral Semaglutide 50 mg Improves Physical Functioning in the OASIS 1 Trial

Obesity (Silver Spring, Md.), 2023-11, Vol.31, p.75-75

2023

Link zum Volltext

Verfügbarkeit prüfen

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial

The Lancet (British edition), 2021-12, Vol.398 (10317), p.2160-2172

2021

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial

A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity‐related risk factors (COR‐II)

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial

Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5

Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses

Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice

Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss

Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program

A Systematic Review of Dietary Supplements and Alternative Therapies for Weight Loss

Weight History in Clinical Practice: The State of the Science and Future Directions

Randomized controlled trial of a nationally available weight control program tailored for adults with type 2 diabetes

Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials

Changes in weight control behaviors and hedonic hunger in a commercial weight management program adapted for individuals with type 2 diabetes

Radioimmunoassay and Tandem Mass Spectrometry Measurement of Bedtime Salivary Cortisol Levels: A Comparison of Assays to Establish Hypercortisolism

Effects of Dietary Self-Monitoring, Physical Activity, Liraglutide 3.0 mg, and Placebo on Weight Loss in the SCALE IBT Trial

Impact on psychosocial outcomes of a nationally available weight management program tailored for individuals with type 2 diabetes: Results of a randomized controlled trial

Efficacy and safety of semaglutide 2.4 mg by race and ethnicity: A post hoc analysis of three randomized controlled trials

Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial

Efficacy and Safety of Semaglutide 2.4 mg by Race and Ethnicity

A review of topiramate and phentermine: a combined therapeutic approach for obesity

Once Daily Oral Semaglutide 50 mg Improves Physical Functioning in the OASIS 1 Trial

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial

Suchergebnisse filtern